Academic Journal
JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience
| العنوان: | JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience |
|---|---|
| المؤلفون: | Chighizola Cecilia B, Pellico Maria Rosa, Pandolfi Marco, Marelli Luca, Cornalba Martina, Pontikaki Irene, Costi Stefania, Gattinara Maurizio, Marino Achille, Miserocchi Elisabetta, Caporali Roberto |
| المساهمون: | Chighizola Cecilia, B, Pellico Maria, Rosa, Pandolfi, Marco, Marelli, Luca, Cornalba, Martina, Pontikaki, Irene, Costi, Stefania, Gattinara, Maurizio, Marino, Achille, Miserocchi, Elisabetta, Caporali, Roberto |
| بيانات النشر: | Clinical and Experimental Rheumatology S.A.S. |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | JAK inhibitor, juvenile idiopathic arthriti, remission, uveitis |
| الوصف: | Objective This study aims to evaluate the efficacy and safety of JAK inhibitors (JAKi) in a monocentric cohort of adult patients with juvenile idiopathic arthritis (JIA). Methods Patients attending a rheumatology transition clinic were retrospectively included in case of: i) JIA diagnosis according to current classification criteria (1); ii) age ≥18 years and iii) treatment with JAKi for at least 3 months. Results Seventeen adult patients with JIA were treated with JAKi (as first JAKi, 9 patients (52.9%) received tofacitinib and 8 (47.1%) baricitinib). At 3 months after JAKi initiation, 8 patients (47%) achieved a response and 4 patients (23.5%) achieved disease remission (3 patients with baricitinib and 1 with tofacitinib, 37.5% vs. 16.7%, p=0.294). None of those with systemic JIA and enthesitis-related arthritis obtained remission; the remission rate at 3 months was higher, although not significantly, in the oligoarticular subset compared to the polyarticular subset (37.5% vs.20%). Patients with ≤1 active joint involvement at JAKi start had a higher remission rate (50% vs.22.2%). Subjects who achieved remission on JAKi had a significantly lower pre-treatment DAS28-CRP compared to those with still active disease (p=0.010, Mann-Whitney U=4). A pre-treatment DAS28-CRP <3.76 predicted response to JAKi with 100% sensitivity and 84.6% specificity (p=0.023). The remission rate was lower among patients who had been treated with ≥2 biological drugs before JAKi start (9% vs. 66.7%; p=0.05). One patient in concomitant treatment with leflunomide developed severe arterial hypertension. Conclusion JAKi may represent an effective and safe treatment option for adult JIA patients with low/moderate disease activity, particularly in case of oligoarticular involvement. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/38530666; volume:42; issue:5; firstpage:974; lastpage:982; numberofpages:9; journal:CLINICAL AND EXPERIMENTAL RHEUMATOLOGY; https://hdl.handle.net/20.500.11768/165377; https://www.clinexprheumatol.org/abstract.asp?a=20066 |
| DOI: | 10.55563/clinexprheumatol/4yoas8 |
| الاتاحة: | https://hdl.handle.net/20.500.11768/165377 https://doi.org/10.55563/clinexprheumatol/4yoas8 https://www.clinexprheumatol.org/abstract.asp?a=20066 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.5057A49E |
| قاعدة البيانات: | BASE |
| DOI: | 10.55563/clinexprheumatol/4yoas8 |
|---|